Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Population Based Analysis of Outcomes of Primary Central Nervous System Lymphoma (PCNSL) Suggests a Treatment Strategy Including Intensive Chemotherapy with Autologous Stem Cell Transplantation Provides a Survival Advantage for Patients <65 Years of Age

Joanna Graczyk, MD FRCPC, Sunita Ghosh, PhD, Neil Chua, MD FRCPC, Douglas A. Stewart, MD FRCPC, Carolyn J. Owen, MD FRCPC

Blood (2014) 124 (21): 2520.

https://doi.org/10.1182/blood.V124.21.2520.2520

Published: 2014

Journal Articles

Autologous Stem Cell Transplantation Improves Survival for Patients with Follicular Lymphoma in First or Second Relapse: Results of a Comparative Effectiveness Instrumental Variable Analysis

Danielle H. Oh, MB ChB, Qiuli Duan, MSc, Anthea Peters, MD MSc, FRCPC, Neil Chua, MD FRCPC, Douglas A. Stewart, MD FRCPC

Blood (2014) 124 (21): 3972.

https://doi.org/10.1182/blood.V124.21.3972.3972

Published: 2014

Journal Articles

Final Report Of a Phase II Clinical Trial Of Lenalidomide Monotherapy For T-Cell Lymphoma

Ethan Toumishey, B. Sc, Angeli Prasad, CCRP, Gregory S. Dueck, MD, MSc, BSc, FRCPC, Neil Chua, MD, FRCPC, Daygen Finch, MD, Douglas A. Stewart, MD, FRCPC, Darrell J. White, MD, Richard H. van der Jagt, MD, FRCPC, James B Johnston, MD, Andrew R Belch, MD, Tony Reiman, MD

Blood (2013) 122 (21): 4376.

https://doi.org/10.1182/blood.V122.21.4376.4376

Published: 2013

Journal Articles

Aggressive Non-Hodgkin Lymphoma: Predictive Value Of Sarcopenia and Skeletal Muscle Density On Prognosis With Rituximab Containing Therapy

Michael P Chu, MD, Jessica Lieffers, Andrew R Belch, MD, Neil Chua, MD, FRCPC, Amelie Fontaine, MD, Randeep Sangha, A. Robert Turner, MD, FRCPC, Sunita Ghosh, PhD, Michael Sawyer, MD

Blood (2013) 122 (21): 3023.

https://doi.org/10.1182/blood.V122.21.3023.3023

Published: 2013

Journal Articles

Indolent Non-Hodgkin Lymphoma: Skeletal Muscle Density Predicts Overall Survival With Rituximab Based Chemotherapy

Michael P Chu, MD, Jessica Lieffers, Andrew R Belch, MD, Neil Chua, MD, FRCPC, Amelie Fontaine, MD, Randeep Sangha, A. Robert Turner, MD, Sunita Ghosh, PhD, Michael Sawyer, MD

Blood (2013) 122 (21): 5078.

https://doi.org/10.1182/blood.V122.21.5078.5078

Published: 2013

Journal Articles

Population-Based Study of the Outcomes of Primary Central Nervous System Lymphoma (PCNSL) In the Era of Autologous Stem Cell Transplantation (ASCT)

Carolyn J Owen, MD, FRCPC, Andrew Daly, MD, FRCPC, Neil Chua, MD, FRCPC, Douglas A. Stewart, MD, FRCP

Blood (2010) 116 (21): 1346.

https://doi.org/10.1182/blood.V116.21.1346.1346

Published: 2010

NARROW

Population Based Analysis of Outcomes of Primary Central Nervous System Lymphoma (PCNSL) Suggests a Treatment Strategy Including Intensive Chemotherapy with Autologous Stem Cell Transplantation Provides a Survival Advantage for Patients <65 Years of Age

Autologous Stem Cell Transplantation Improves Survival for Patients with Follicular Lymphoma in First or Second Relapse: Results of a Comparative Effectiveness Instrumental Variable Analysis

Final Report Of a Phase II Clinical Trial Of Lenalidomide Monotherapy For T-Cell Lymphoma

Aggressive Non-Hodgkin Lymphoma: Predictive Value Of Sarcopenia and Skeletal Muscle Density On Prognosis With Rituximab Containing Therapy

Indolent Non-Hodgkin Lymphoma: Skeletal Muscle Density Predicts Overall Survival With Rituximab Based Chemotherapy

Population-Based Study of the Outcomes of Primary Central Nervous System Lymphoma (PCNSL) In the Era of Autologous Stem Cell Transplantation (ASCT)

Email alerts

ASH Publications

American Society of Hematology

Population Based Analysis of Outcomes of Primary Central Nervous System Lymphoma (PCNSL) Suggests a Treatment Strategy Including Intensive Chemotherapy with Autologous Stem Cell Transplantation Provides a Survival Advantage for Patients <65 Years of Age

Autologous Stem Cell Transplantation Improves Survival for Patients with Follicular Lymphoma in First or Second Relapse: Results of a Comparative Effectiveness Instrumental Variable Analysis

Final Report Of a Phase II Clinical Trial Of Lenalidomide Monotherapy For T-Cell Lymphoma

Aggressive Non-Hodgkin Lymphoma: Predictive Value Of Sarcopenia and Skeletal Muscle Density On Prognosis With Rituximab Containing Therapy

Indolent Non-Hodgkin Lymphoma: Skeletal Muscle Density Predicts Overall Survival With Rituximab Based Chemotherapy

Population-Based Study of the Outcomes of Primary Central Nervous System Lymphoma (PCNSL) In the Era of Autologous Stem Cell Transplantation (ASCT)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only